During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

Raad B. Chowdhury, MD, and Shruti Gupta, MD, MPH, are onconephrologists in the Division of Nephrology at Brigham and Women's ...

While doctors determined he broke his right clavicle, they wanted to do a follow-up MRI to understand why. The reason felt ...

GAGome scores had 90% sensitivity and 51% specificity for radiological recurrence, with an AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma. HealthDay News — Urine glycosaminoglycan ...

Figure 4. Performance of the risk factors in differentiating angiomyolipoma without visible fat (AML.wovf) from clear cell renal cell carcinoma (ccRCC) determined by receiver operating characteristic ...

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license Self-reported Black (B) individuals remain underrepresented in molecular studies of ...

clear cell carcinoma, and carcinosarcoma) but fell to 36% for atypical hyperplasia. Additional studies are underway to further develop and validate the approach, Bakkum-Gamez said. The work is ...

A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn’s ... and the New Jersey Commission on Cancer Research.

"The versatility of this nano-adjuvant could also lend itself to application for other advanced solid tumours that require enhanced T-cell recognition – such as ovarian cancer," Professor Yu said.